Michael Aberman, M.D., President, CEO, and Co-Founder, is a biotechnology executive with over 20-years’ experience. Previously, he was the president and chief executive officer of Quentis Therapeutics, an early-stage biotech company. Prior to joining Quentis, Dr. Aberman spent over seven years at Regeneron Pharmaceuticals as the Senior Vice President of Investor Relations and Strategy. In that role, Dr. Aberman was a member of the senior management team and was responsible for the investor relations, corporate communications, business development, and corporate strategy functions at Regeneron. Prior to joining Regeneron, Dr. Aberman spent six years as a Wall Street research analyst covering the biotechnology industry at Credit Suisse and Morgan Stanley. Before moving to Wall Street, Dr. Aberman was Director of Business Development at Antigenics, Inc., an oncology-focused biotechnology company. Dr. Aberman currently serves on the board of directors at Unnatural Products.

Dr. Aberman is a received B.A. from Cornell University (’93), his medical degree from the University of Toronto (’97), completed residency training at New York Presbyterian Hospital, and received an M.B.A. from The Wharton School of Business (’01).

Dr. Neil H. Bander is the Bernard and Josephine Chaus Professor in Urological Oncology and Director of Urological Oncology Research at Weill Cornell Medicine. His team at Weill Cornell Medicine has the world’s largest experience in antibody discovery and clinical development in urological cancers. His group developed the first monoclonal antibodies to prostate-specific membrane antigen (PSMA) that could successfully target prostate cancers in patients. This enabled them to define much of the biology of PSMA and clinically validate PSMA as a target in prostate and other cancers. As a result of Dr. Bander and his team’s pioneering efforts, PSMA has become a target of substantial interest and activity in bio-pharma.

Dr. Bander is a surgeon-scientist trained in urological oncology and tumor immunology, both at Memorial Sloan Kettering Cancer Center. He has authored approximately 200 peer-reviewed publications, and he is an inventor on approximately 150 US and foreign issued and pending patents. He has served on, and chaired, multiple study sections and grant review panels and received several honors including the FC Valentine Fellowship from the NY Academy of Medicine, the Society of Surgical Oncology James Ewing Research Award, awards from the German and Japanese Urology Societies, the Prostate Cancer Foundation, and the Clark Medal for Surgical Innovation from the Royal College of Surgeons (London). He also serves on several industry Scientific Advisory Boards.

Mr. Fallace (Dave) is a Managing Partner and Co-Founder of Cure Ventures. He has made investments in venture capital and alternative asset funds for over 20 years. He served as a member of the investment committee of several large multibillion-dollar firms overseeing alternative investment portfolios. Across these portfolios he made investments as a limited partner and as a founding investor in start-ups. Most recently, Dave served as an advisor for the biotech venture capital fund Polaris Partners where he evaluated Biotechnology and Health Care Information Technologies investments. During this period, he also served as an Expert-in-Resident program at Harvard University’s Office of Technology Development. Prior to Polaris, he served as a Managing Director and member of the investment committee heading the $2.5 billion diversifying strategies at TIFF Investment Management.

From 2013 to 2016, Dave served as the Director of Investments leading the $10 billion Special Opportunities program at the Alaska Permanent Fund Corporation. He spearheaded their direct venture investing serving as a board observer at Juno Therapeutics (Acquired by Celgene), and Denali Therapeutics (NASDAQ: DNLI). Starting in 2000, Dave worked at GF Private Equity Group managing private equity and hedge fund portfolios in addition to investing in direct venture capital transactions. He served on the board or board observer of Ahura (Acquired Thermo Fisher), Alfalight (Acquired Gooch & Housego), Kotura (Acquired Mellanox), Pathscale (Acquired QLogic), Teros (Acquired Citrix), and Impinj (NASDAQ:PI). Dave received his B.A. from Stony Brook University and his M.B.A. and J.D. from the State University of New York at Buffalo focusing on tax and financial structuring and is a member of the New York Bar.

Rich's career in the life science sector spans three decades demonstrating strategic and corporate development leadership within the biotech industry as well as investment leadership at top-performing venture capital firms. He is considered a trusted partner to visionary scientists and entrepreneurs, by being directly involved in the early capital raises of leading prominent biotech start-ups. From 2020 to 2021, Rich served as Chief Business Officer and SVP of Corporate Development for an oncology focused biopharmaceutical company, where he led all deal-making activities including acquisitions, licensing, and partnerships. As a member of the senior executive team, Richard contributed to the company becoming one of the top 5 biopharma IPOs of 2020.

From 2008 to 2020, Rich served as a Managing Member and President of top quartile performing Omega Funds, where he sourced, conducted diligence, raised capital and served for many of Omega's most successful portfolio companies. He served on the Board of Directors for Nuvation Bio (NASDAQ: NUVB), Gossamer Bio (NASDAQ: GOSS), and Replimune (NASDAQ: REPL)and Paratek Pharmaceuticals (NASDAQ: PRTK).

Previously, Rich was a Managing Director of MVM Life Science Partners LLP, where he founded MVM's US operations and sourced all US deals during his tenure. Before MVM, Rich was Vice President at Saunders Karp & Megrue, a private equity firm, where he focused on healthcare equity deals. Rich was also Engagement Manager at LEK Consulting, a strategy and mergers & acquisitions consulting firm where he advised leading biotech and pharma companies. Mr. Lim received his A.B. from Harvard College and M.B.A. from Harvard Business School.